Traumatic Brain Injury (TBI) Clinical Trial Pipeline Analysis: 40+ Key Companies Shaping the Future of Traumatic Brain Injury Therapeutics | DelveInsight

DelveInsight's Traumatic Brain Injury Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Traumatic Brain Injury therapies in various stages of clinical development. The report provides insights into 40+ companies and 50+ pipeline drugs in the Traumatic Brain Injury pipeline landscape, covering clinical and nonclinical stage products, therapeutic assessments, and inactive pipeline products.

Key takeaways from the Traumatic Brain Injury Clinical Trial Landscape Report

• DelveInsight's Traumatic Brain Injury pipeline report depicts a robust space with 40+ companies working to develop 50+ pipeline therapies for Traumatic Brain Injury treatment.
• Key Traumatic Brain Injury companies such as Biomed Industries, SHINKEI Therapeutics, Oragenics, Dompé farmaceutici, BEYOND Barriers Therapeutics, Grey Matter Health, GryPhon Bio, Alpha Cognition, Alcamena, Applied Cognition, Silver Creek Pharmaceuticals, Azevan Pharmaceuticals, NOVEOME Biotherapeutics, Inc., Neuroplast, Addex therapeutics, Ischemix, Inc., AlzeCure Pharma AB, Matricelf, AivoCode, International Stemcell Corporation, Mitochon Pharmaceuticals, NervGen Pharma, Tiziana Life Sciences, and others.
• Promising Traumatic Brain Injury pipeline therapies in various stages of development include NA-731, MR-301, ONP-002, BBT-101, AP-188, OWL-1410, ALPHA-1062, ASCT-83, ACX-02, SCP776, SRX251, ST266, Neuro-cell, Diplaglurant, CMX-2043, ACD856, AC01, ISC-hpNSC, MP201, NVG-291, Foralumab, and others.

Request a sample and discover the recent advances in Traumatic Brain Injury treatment drugs: https://www.delveinsight.com/sample-request/traumatic-brain-injury-tbi-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Traumatic Brain Injury (TBI)?

Traumatic brain injury (TBI) is a major global health concern caused by external mechanical forces, including direct impact, rapid acceleration-deceleration, or penetrating head injuries, resulting in temporary or permanent impairment of brain function, disability, or death.
TBIs are broadly classified into penetrating (open) injuries, in which an object breaches the skull and directly damages brain tissue, and nonpenetrating (closed) injuries, where external force causes the brain to move within an intact skull. Common causes include falls, motor vehicle accidents, sports injuries, blast exposure, and blunt trauma. Brain injury may be primary, occurring at the time of trauma, or secondary, developing over hours to weeks through progressive pathological processes.
Based on clinical presentation and the Glasgow Coma Scale (GCS), TBI is categorized as mild (GCS 14-15), moderate (GCS 9-12), or severe (GCS 3-8), with mild TBI or concussion accounting for more than 90% of cases. Falls are the leading cause of TBI, particularly among children and older adults, followed by motor vehicle collisions, sports- and work-related injuries, and assaults.
Common physical manifestations include headache, dizziness, confusion, fatigue, and irritability, while severe symptoms may include persistent headache, seizures, blurred or double vision, unequal pupils, recurrent vomiting, slurred speech, limb weakness, and impaired balance. Cognitive and behavioral symptoms can include memory and concentration deficits, impaired decision-making, sleep disturbances, anxiety, depression, agitation, and irritability.
Diagnosis of TBI requires a comprehensive and timely approach combining clinical evaluation, neuroimaging, laboratory investigations, and standardized decision tools. Non-contrast computed tomography (CT) is the first-line imaging modality for detecting acute intracranial injuries, while magnetic resonance imaging (MRI) is more sensitive for identifying subtle lesions, including diffuse axonal injury.
The primary goal of TBI management is to prevent secondary brain injury through early stabilization, maintenance of adequate cerebral perfusion, and prompt treatment of life-threatening complications. Mild TBI is typically managed with neurological assessment, selective CT imaging, observation when appropriate, and follow-up, while moderate-to-severe TBI requires intensive care, continuous neurological monitoring, intracranial pressure management, timely surgical intervention when indicated, and evidence-based supportive care.

Emerging Traumatic Brain Injury Drug Profiles

Autologous HB-adMSCs: Hope Biosciences LLC
Autologous HB-adMSCs are adipose-derived mesenchymal stem cells obtained from the patient and expanded for therapeutic use. They act mainly through immunomodulation, anti-inflammatory effects, and paracrine signaling that supports neural repair and reduces neuroinflammation following TBI. These cells may also promote tissue regeneration and support recovery of damaged brain function. HB-adMSCs are currently being evaluated in clinical studies, with Phase I safety studies completed and Phase II trials ongoing to assess efficacy and neurological outcomes.

BBT-101: BEYOND Barriers Therapeutics
BBT-101 is a first-in-class intranasal formulation of N-acetylcysteine (NAC) being developed for the treatment of mild and moderate traumatic brain injury. Designed to enhance brain glutathione levels and reduce neuroinflammation, oxidative stress, and cerebral edema, BBT-101 utilizes a patented nose-to-brain delivery platform designed to bypass first-pass metabolism and improve brain targeting.
Developed through the FDA's 505(b)(2) regulatory pathway, BBT-101 is currently being evaluated in an investigator-sponsored Phase Ib/IIa clinical trial in emergency department patients with concussion/TBI, with an additional study planned in collegiate athletes.

ST266: NOVEOME Biotherapeutics, Inc.
ST266 is a first-of-its-kind, multi-targeted, noncellular biologic being developed by NOVEOME Biotherapeutics, Inc. Derived from the secretome of amnion-derived multipotent progenitor cells, ST266 comprises a complex mixture of cytokines, growth factors, and extracellular vesicles that collectively exert anti-inflammatory, neuroprotective, and regenerative effects.
In TBI, ST266 is designed to modulate multiple biological pathways involved in secondary injury processes, including neuroinflammation, oxidative stress, and neuronal cell death. The therapy can be administered via non-invasive routes such as intranasal delivery, enabling direct targeting of the central nervous system. According to the company's pipeline, ST266 is in the Phase I stage of development for the treatment of TBI.

Learn more about the novel and emerging Traumatic Brain Injury pipeline therapies: https://www.delveinsight.com/sample-request/traumatic-brain-injury-tbi-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the Traumatic Brain Injury Pipeline Report

• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Phase III, Phase II, Phase I, Preclinical, Discovery
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
• Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
• Key Traumatic Brain Injury Companies: Biomed Industries, SHINKEI Therapeutics, Oragenics, Dompé farmaceutici, BEYOND Barriers Therapeutics, Grey Matter Health, GryPhon Bio, Alpha Cognition, Alcamena, Applied Cognition, Silver Creek Pharmaceuticals, Azevan Pharmaceuticals, NOVEOME Biotherapeutics, Inc., Neuroplast, Addex therapeutics, Ischemix, Inc., AlzeCure Pharma AB, Matricelf, AivoCode, International Stemcell Corporation, Mitochon Pharmaceuticals, NervGen Pharma, Tiziana Life Sciences
• Key Traumatic Brain Injury Pipeline Therapies: NA-731, MR-301, ONP-002, BBT-101, AP-188, OWL-1410, ALPHA-1062, ASCT-83, ACX-02, SCP776, SRX251, ST266, Neuro-cell, Diplaglurant, CMX-2043, ACD856, AC01, ISC-hpNSC, MP201, NVG-291, Foralumab

Dive deep into rich insights for new drugs for Traumatic Brain Injury treatment, visit: https://www.delveinsight.com/sample-request/traumatic-brain-injury-tbi-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

1. Traumatic Brain Injury Pipeline Report Introduction
2. Traumatic Brain Injury Pipeline Report Executive Summary
3. Traumatic Brain Injury Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Traumatic Brain Injury Pipeline Therapeutics
6. Traumatic Brain Injury Pipeline: Late Stage Products (Phase III)
7. Traumatic Brain Injury Pipeline: Mid Stage Products (Phase II)
8. Traumatic Brain Injury Pipeline: Early Stage Products (Phase I)
9. Traumatic Brain Injury Pipeline: Preclinical and Discovery Stage Products
10. Traumatic Brain Injury Pipeline Therapeutics Assessment
11. Inactive Products in the Traumatic Brain Injury Pipeline
12. Key Companies
13. Key Products in the Traumatic Brain Injury Pipeline
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix
For further information on the Traumatic Brain Injury pipeline therapeutics, reach out: https://www.delveinsight.com/sample-request/traumatic-brain-injury-tbi-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +1-469-945-7679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, DelveInsight offers customized research solutions and insights to clients across the globe.

This release was published on openPR.